Citations

Clear

119 citation(s) found for "Sheehan, J".

Vestibular Schwannoma Koos Grade II International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS-K2 Study
Bin-Alamer, Othman , Peker, Selçuk , Samanci, Yavuz, Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj , Schulder, Michael , Tourigny, Jean-Nicolas, Hamel, Andréanne, Briggs, Robert G. , Yu, Cheng , Zada, Gabriel , Giannotta, Steven L., Palque, Sarai, Kumar, Narendra , Rogowski, Brandon, Shepard, Matthew J., Warnick, Ronald E. , Dayawansa, Sam , Vasconcellos, Fernando De Nigris , Bernstein, Kenneth , Sheehan, Jason P. , Samancı, Yavuz , Johnson, Bryan A, Sheehan, Jason , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mathieu, David , Giannotta, Steven L. , Speckter, Herwin , Tripathi, Manjul , Kumar, Saurabh , Kaur, Rupinder , Johnson, Bryan A., Trifiletti, Daniel M. , Mashiach, Elad , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas

Mayo Clinic

Neurosurgery | November 6, 2024 | Volume: 96 | Issue: 1 | Pages: 50-58

10.1227/neu.0000000000003216 | PMID 39503444 Get It

BACKGROUND AND OBJECTIVES: This study assessed the efficacy and safety of stereotactic radiosurgery (SRS) in comparison with watchful waiting for managing Koos grade II vestibular schwannomas (VS). METHODS: A retrospective, multicentric analysis was conducted, focusing on patients with Koos grade II VS who either received SRS (SRS group) or were observed (observation group). To ensure comparability between groups, propensity score matching was used, including factors such as demographic characteristics, tumor dimensions, and hearing assessments. The primary end points examined were tumor control, maintenance of serviceable hearing, and neurological outcomes. RESULTS: A total of 92 patients were equally matched across both cohorts, with a median follow-up of 37 months for the SRS group and 27.5 months for those observed. The SRS cohort exhibited superior tumor control over observation across 3, 5, and 8 years, achieving a 100% control rate vs 47.9%, 40.1%, and 34.3% for the observation group at these time intervals, respectively ( P < .001). Serviceable hearing preservation rates were comparable between the 2 groups throughout 3, 5, and 7 years (72.9% for SRS vs 65.4% for observation at 3 years; P = .86). Moreover, SRS management correlated with a lower incidence of vestibular symptoms (odds ratio = 0.11, P = .002), with no significant disparity in the deterioration of cranial nerve (CN) V or CN VII functions. Notably, the likelihood of experiencing any CN impairment was significantly diminished in the SRS cohort (odds ratio = 0.47, P = .04). CONCLUSION: For patients with Koos grade II VS, SRS offers superior tumor control rate and a lower risk of CN dysfunction without sacrificing hearing preservation.
Pediatric cranial stereotactic radiosurgery: Meta-analysis and international stereotactic radiosurgery society practice guidelines
Murphy, Erin S. , Sahgal, Arjun , Régis, Jean , Gorgulho, Alessandra, Ma, Lijun , Pollock, Bruce E. , Yomo, Shoji , Sheehan, Jason P. , Saxena, Anshul, Ahmed, Md Ashfaq, Kotecha, Rupesh , Pollock, Bruce, Paddick, Ian , Kotecha, Rupesh , Levivier, Marc , Fariselli, Laura , Paddick, Ian , Suh, John H.

Mayo Clinic

Neuro-Oncology | October 11, 2024 | Volume: 27 | Issue: 2 | Pages: 517-532

10.1093/neuonc/noae204 | PMID 39390948 Get It

Abstract Background There are limited data on the use of stereotactic radiosurgery (SRS) for pediatric patients. The aim of this systematic review was to summarize indications and outcomes specific to pediatric cranial SRS to inform consensus guidelines on behalf of the International Stereotactic Radiosurgery Society. Methods A systematic review, using the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses, analyzed English-language articles on SRS, published between 1989 and 2021, that included outcomes for at least 5 pediatric patients. MEDLINE database terms included tumor types and locations, and radiosurgical and age-specific terms. We excluded nonclinical reports, expert opinions, commentaries, and review articles. Meta-regressions for associations with local control were performed for medulloblastoma, craniopharyngioma, ependymoma, glioma, and arteriovenous malformation (AVM). Results Of the 113 articles identified for review, 68 met the inclusion criteria. These articles described approximately 400 pediatric patients with benign and malignant brain tumors and 5119 with AVMs who underwent cranial SRS. The rates of local control for benign tumors, malignant tumors, and AVMs were 89% (95% CI, 82%–95%), 71% (95% CI, 59%–82%), and 65% (95% CI, 60%–69%), respectively. No significant associations were identified for local control with the patient-, tumor-, or treatment-related variables. Conclusions This review is the first to summarize outcomes specific to SRS for pediatric brain tumors and AVMs. Although data reporting is limited for pediatric patients, SRS appears to provide acceptable rates of local control. We present ISRS consensus guidelines to inform the judicious use of cranial SRS for pediatric patients.
Microsurgical Treatment of Intracranial Dural Arteriovenous Fistulas: A Collaborative Investigation From the Multicenter Consortium for Dural Arteriovenous Fistula Outcomes Research
Raygor, Kunal P. , Abdelsalam, Ahmed , Raper, Daniel , Guniganti, Ridhima , Durnford, Andrew , Brinjikji, Waleed , Abecassis, Isaac Josh, Polifka, Adam , Samaniego, Edgar A. , Kwasnicki, Amanda , Potgieser, Adriaan R. E., Tada, Yoshiteru , Kansagra, Akash P. , Satomi, Junichiro, Eatz, Tiffany , Peterson, Eric C. , Starke, Robert M., Dijk, J. Marc C. van , Hayakawa, M. , Gross, Bradley A. , Fox, W. Christopher, Kim, Louis J. , Sheehan, Jason , Bulters, Diederik , Zipfel, Gregory J. , Abla, Adib A. , Alaraj, Ali , Eatz, Tiffany , Alaraj, Ali , Samaniego, Edgar A , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Tonetti, Daniel A. , Giordan, Enrico , Chen, Ching‐Jen , Levitt, Michael R. , Derdeyn, Colin P. , Chen, Stephanie , Peterson, Eric C., Amin-Hanjani, Sepideh , Gross, Bradley , Fox, W Christopher , Kim, Louis J. , Lanzino, Giuseppe , Du, Rose , Lai, Pui Man Rosalind

Mayo Clinic

Neurosurgery | October 8, 2024 | Volume: 96 | Issue: 5 | Pages: 1023-1034

10.1227/neu.0000000000003204 | PMID 39471093 Get It

BACKGROUND AND OBJECTIVES: First-line therapy for most intracranial dural arteriovenous fistulas (dAVFs) is endovascular embolization, but some require microsurgical ligation due to limited endovascular accessibility, anticipated lower cure rates, or unacceptable risk profiles. We investigated the most common surgically treated dAVF locations and the approaches and outcomes of each. METHODS: The Consortium for Dural Arteriovenous Fistula Outcomes Research database was retrospectively reviewed. Patients who underwent dAVF microsurgical ligation were included. Patient demographics, angiographic information, surgical details, and postoperative outcomes were collected. The 5 most common surgically treated dAVF locations were analyzed about used surgical approaches and postoperative outcomes. Univariate analyses were performed with statistical significance set at a threshold of P < .05. RESULTS: In total, 248 patients in the Consortium for Dural Arteriovenous Fistula Outcomes Research database met inclusion criteria. The 5 most common surgically treated dAVF locations were tentorial, anterior cranial fossa (ACF), transverse-sigmoid sinus (TSS), convexity/superior sagittal sinus (SSS), and torcular. Most tentorial dAVFs were approached using a suboccipital, lateral supracerebellar infratentorial approach (39.3%); extended retrosigmoid approach (ERS) (25%); or posterior subtemporal approach (19.6%). All ACF dAVFs used a subfrontal approach; 5.3% also included an anterior interhemispheric approach. Most TSS dAVFs were ligated via ERS (31.3%) or subtemporal (31.3%) approaches. All convexity/SSS dAVFs used an interhemispheric approach. All torcular dAVFs used the suboccipital, lateral supracerebellar infratentorial approach, with 10.5% undergoing simultaneous ERS craniotomy. Angiographic occlusion rates after microsurgery were 85.5%, 100%, 75.8%, 79.2%, and 73.7% for tentorial, ACF, TSS, convexity/SSS, and torcular dAVFs, respectively ( P = .02); the permanent neurological complication rates were 1.8%, 2.6%, 9.1%, 0%, and 0% ( P = .31). There were no statistically significant differences in development of complications ( P = .08) or Modified Rankin Scale at the last follow-up ( P = .11) by fistula location. CONCLUSION: Although endovascular embolization is the first-line treatment for most intracranial dAVFs, surgical ligation is an important alternative. ACF and tentorial fistulas particularly demonstrate high rates of postoperative obliteration.
Comparing stand-alone endovascular embolization versus stereotactic radiosurgery in the treatment of arteriovenous malformations with Spetzler-Martin grades I–III: a propensity score matched study
Musmar, Basel , Adeeb, Nimer , Roy, Joanna M. , Abdalrazeq, Hammam , Tjoumakaris, Stavropoula , Atallah, Elias , Salim, Hamza , Sheehan, Jason , Ogilvy, Christopher S. , Riina, Howard A. , Naamani, Kareem El, Ironside, Natasha , Ataoglu, Cagdas , Essibayi, Muhammed Amir , Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Erginoğlu, Ufuk , Sen, Rajeev , Burkhardt, Jan‐Karl , Starke, Robert M., Başkaya, Mustafa K. , Altschul, David , McAvoy, Malia , Aslan, Assala , Abushehab, Abdallah, Swaid, Christian, Abla, Adib A. , Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Dannenbaum, Mark J. , Pukenas, Bryan , Smith, Edward, Alaraj, Ali , Patel, Aman B. , Cuellar, Hugo H, Lawton, Michael T. , Guthikonda, Bharat , Jabbour, Pascal , Smith, Edward R. , Tjoumakaris, Stavropoula , Salim, Hamza , Ogilvy, Christopher S , Kandregula, Sandeep , Dmytriw, Adam A , Essibayi, Muhammed Amir , Griessenauer, Christoph J , Levitt, Michael R , Altschul, David J , Aslan, Assala , Stapleton, Christopher , Koch, Matthew J , Chen, Peng R , Dannenbaum, Mark J , Choudhri, Omar , Alaraj, Ali , Guthikonda, Bharat , Jabbour, Pascal , Abla, Adib , Musmar, Basel , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Kondziolka, Douglas , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Rezai, Arwin, Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Sekhar, Laligam N. , Levitt, Michael R. , Gooch, Michael Reid , Blackburn, Spiros , Choudhri, Omar , Orbach, Darren B. , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

Journal of NeuroInterventional Surgery | October 4, 2024 | Volume: 17 | Issue: 12 | Pages: 1382-1390

10.1136/jnis-2024-022326 | PMID 39366733 Get It

Background Arteriovenous malformations (AVMs) are uncommon cerebral lesions that can cause significant neurological complications. Surgical resection is the gold standard for treatment, but endovascular embolization and stereotactic radiosurgery (SRS) are viable alternatives. Objective To compare the outcomes of endovascular embolization versus SRS in the treatment of AVMs with Spetzler-Martin grades I–III. Methods This study combined retrospective data from 10 academic institutions in North America and Europe. Patients aged 1 to 90 years who underwent endovascular embolization or SRS for AVMs with Spetzler-Martin grades I–III between January 2010 and December 2023 were included. Results The study included 244 patients, including 84 who had endovascular embolization and 160 who had SRS. Before propensity score matching (PSM), complete obliteration at the last follow-up was achieved in 74.5% of the SRS group compared with 57.8% of the embolization group (OR=0.47; 95% CI 0.26 to 0.48; P=0.01). After propensity score matching, SRS still achieved significantly higher occlusion rates at last follow-up (78.9% vs 55.3%; OR=0.32; 95% CI 0.12 to 0.90; P=0.03). Hemorrhagic complications were higher in the embolization group than in the SRS group, although this difference did not reach statistical significance after PSM (13.2% vs 2.6%; OR=5.6; 95% CI 0.62 to 50.47; P=0.12). Similarly, re-treatment rate was higher in the embolization group (10.5% vs 5.3%; OR=2.11; 95% CI 0.36 to 12.31; P=0.40) compared with the SRS group. Conclusion Our findings indicate that SRS has a significantly higher obliteration rate at last follow-up compared with endovascular embolization. Also, SRS has a higher tendency for fewer hemorrhagic complications and lower re-treatment rate. Further prospective studies are needed.
Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis
Armstrong, April W. , Lim, Henry W., Johnson, Sandra Marchese , Claiborne, W. C. Cole, Kalb, Robert E. , Jakus, Jeannette , Mangold, Aaron R. , Bagel, Jerry , Fretzin, Scott , Sheehan, Michael P. , Krell, James, Reeder, Margo J. , Kartono, Francisca, Bridges, Alisha, Nehal, Umbereen S., Schaecher, Kenneth L., Howard, Leah, Eakin, Guy S. , Báez, Suzette , Bishop, Brooke E., Fitzsimmons, Robert C., Papadopoulos, Maryte , Song, William B. , Linn, Kristin A. , Duffin, Kristina Callis , Mangold, A R , Gelfand, Joel M. , Lim, Henry W. , Feldman, Steven R. , Flowers, Richard Hal , Bhutani, Tina , Durkin, John R. , Kaffenberger, Jessica A. , Takeshita, Junko , Fielding, Eric Jameson , Bishop, B., Fitzsimmons, Robert C. , Hubbard, Rebecca A. , Shin, Daniel B.

Mayo Clinic

JAMA Dermatology | September 25, 2024 | Volume: 160 | Issue: 12 | Pages: 1320

10.1001/jamadermatol.2024.3897 | PMID 39319513 Get It

Importance Office-based phototherapy is cost-effective for psoriasis but difficult to access. Home-based phototherapy is patient preferred but has limited clinical data, particularly in patients with darker skin. Objective To compare the effectiveness of home- vs office-based narrowband UV-B phototherapy for psoriasis. Design, Setting, and Participants The Light Treatment Effectiveness study was an investigator-initiated, pragmatic, open-label, parallel-group, multicenter, noninferiority randomized clinical trial embedded in routine care at 42 academic and private clinical dermatology practices in the US. Enrollment occurred from March 1, 2019, to December 4, 2023, with follow-up through June 2024. Participants were 12 years and older with plaque or guttate psoriasis who were candidates for home- and office-based phototherapy. Interventions Participants were randomized to receive a home narrowband UV-B machine with guided mode dosimetry or routine care with office-based narrowband UV-B for 12 weeks, followed by an additional 12-week observation period. Main Outcomes and Measures The coprimary effectiveness outcomes were Physician Global Assessment (PGA) dichotomized as clear/almost clear skin (score of ≤1) at the end of the intervention period and Dermatology Life Quality Index (DLQI) score of 5 or lower (no to small effect on quality of life) at week 12. Results Of 783 patients enrolled (mean [SD] age, 48.0 [15.5] years; 376 [48.0%] male), 393 received home-based phototherapy and 390 received office-based phototherapy, with 350 (44.7%) having skin phototype (SPT) I/II, 350 (44.7%) having SPT III/IV, and 83 (10.6%) having SPT V/VI. A total of 93 patients (11.9%) were receiving systemic treatment. At baseline, mean (SD) PGA was 2.7 (0.8) and DLQI was 12.2 (7.2). At week 12, 129 patients (32.8%) receiving home-based phototherapy and 100 patients (25.6%) receiving office-based phototherapy achieved clear/almost clear skin, and 206 (52.4%) and 131 (33.6%) achieved DLQI of 5 or lower, respectively. Home-based phototherapy was noninferior to office-based phototherapy for PGA and DLQI in the overall population and across all SPTs. Home-based phototherapy, compared to office-based phototherapy, was associated with better treatment adherence (202 patients [51.4%] vs 62 patients [15.9%]; P &amp;lt; .001), lower burden of indirect costs to patients, and more episodes of persistent erythema (466 of 7957 treatments [5.9%] vs 46 of 3934 treatments [1.2%]; P &amp;lt; .001). Both treatments were well tolerated with no discontinuations due to adverse events. Conclusions and Relevance In this randomized clinical trial, home-based phototherapy was as effective as office-based phototherapy for plaque or guttate psoriasis in everyday clinical practice and had less burden to patients. Trial Registration ClinicalTrials.gov Identifier: NCT03726489
Stereotactic Radiosurgery With Versus Without Neoadjuvant Endovascular Embolization for Brain Arteriovenous Malformations With Associated Intracranial Aneurysms
Becerril‐Gaitan, Andrea , Nguyen, Justin H. , Lee, Cheng‐Chia , Ding, Dale , Woo, Shiao Y. , Warnick, Ronald E. , Feliciano, Caleb , Rodriguez-Mercado, R, Cockroft, Kevin M. , Simon, Scott D. , Lee, John, Sheehan, Jason P. , Chen, Ching-Jen , Ding, Dale , Nguyen, Justin, Cifarelli, Christopher P. , Liščák, Roman , Williams, Brian J. , Yusuf, Mehran Behruj , Trifiletti, Daniel M. , Mathieu, David , Kondziolka, Douglas , Lee, John, Chen, Ching‐Jen

Mayo Clinic

Neurosurgery | August 22, 2024 | Volume: 96 | Issue: 4 | Pages: 787-793

10.1227/neu.0000000000003152 | PMID 39171929 Get It

BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) with neoadjuvant embolization is a treatment strategy for brain arteriovenous malformations (AVMs), especially for those with large nidal volume or concomitant aneurysms. The aim of this study was to assess the effects of pre-SRS embolization in AVMs with an associated intracranial aneurysm (IA). METHODS: The International Radiosurgery Research Foundation AVM database from 1987 to 2018 was retrospectively reviewed. SRS-treated AVMs with IAs were included. Patients were categorized into those treated with upfront embolization (E + SRS) vs stand-alone SRS (SRS). Primary end point was a favorable outcome (AVM obliteration + no permanent radiation-induced changes or post-SRS hemorrhage). Secondary outcomes included AVM obliteration, mortality, follow-up modified Rankin Scale, post-SRS hemorrhage, and radiation-induced changes. RESULTS: Forty four AVM patients with associated IAs were included, of which 23 (52.3%) underwent pre-SRS embolization and 21 (47.7%) SRS only. Significant differences between the E + SRS vs SRS groups were found for AVM maximum diameter (1.5 ± 0.5 vs 1.1 ± 0.4 cm 3 , P = .019) and SRS treatment volume (9.3 ± 8.3 vs 4.3 ± 3.3 cm 3 , P = .025). A favorable outcome was achieved in 45.4% of patients in the E + SRS group and 38.1% in the SRS group ( P = .625). Obliteration rates were comparable (56.5% for E + SRS vs 47.6% for SRS, P = .555), whereas a higher mortality rate was found in the SRS group (19.1% vs 0%, P = .048). After adjusting for AVM maximum diameter, SRS treatment volume, and maximum radiation dose, the likelihood of achieving favorable outcome and AVM obliteration did not differ between groups ( P = .475 and P = .820, respectively). CONCLUSION: The likelihood of a favorable outcome and AVM obliteration after SRS with neoadjuvant embolization in AVMs with concomitant IA seems to be comparable with stand-alone SRS, even after adjusting for AVM volume and SRS maximum dose. However, the increased mortality among the stand-alone SRS group and relatively low risk of embolization-related complications suggest that these patients may benefit from a combined treatment approach.
QSPC-03 PATIENT-REPORTED QUALITY OF LIFE AFTER UNDERGOING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES: A PROSPECTIVE ASSESSMENT UTILIZING A U.S. NATIONAL REGISTRY
BA, Duy Pham, Sheehan, Darrah, Sheehan, Kimball , Sheehan, Jason P. , MBBS, Konstantinos Katsos, Fadul, Camilo E.

Mayo Clinic

Neuro-Oncology Advances | August 3, 2024 | Volume: 6 | Issue: Supplement_1 | Pages: i37-i37

10.1093/noajnl/vdae090.121 Get It

Abstract Patients with brain metastases (BMETS) frequently emphasize the impact on quality of life (QOL) over prolongation of life at the time of making treatment decisions. Thus, it is critical to evaluate patient-reported health utility scores after treatment of BMETS. Stereotactic surgery (SRS) is becoming the most frequent treatment modality. The objective of this study was to determine the changes in the EuroQol- 5 Dimension (EQ-5D) in patients with BMETS treated with SRS. The NPA SRS Registry is a multi-institutional collaboration prospectively collecting information from patients undergoing SRS since 2017. We queried the registry for the results of the baseline and follow-up EQ-5D questionnaire, with a utility index score given based on the patient’s responses for five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The cohort included 522 cases treated with SRS between 2017 and 2023; 264 (47.8%), 197 (35.7%), and 91 (16.5%) had 1, 2-4, and 5-14 metastases, respectively. The mean EQ-5D score at the time of SRS was 0.551 (SD=0.443). At the last follow-up after SRS, 107 (34.0%) patients indicated improvement from their EQ-5D baseline while 51 (16.2%) were stable. The score decreased in 113 patients (35.9%) while 44 (13.9%) showed mixed changes (i.e., domain sub-scores both increased and decreased). For mobility, usual activities, pain/discomfort, and anxiety/depression domains patients experienced similar rates of improvement (21.0%-22.5%). In the self-care domain, 32 (10.2%) patients reported improvement, 232 (73.7%) reported no change and 89 (28.3%) had worsening scores. Our study provided the first longitudinal prospective real-world data using the EQ-5D, a health utility tool, in patients with BMETS treated with SRS. In more than half of the cases, the patients reported improved or stable EQ-5D scores over time after treatment. Factors independent of treatment that may prompt worsening QOL following SRS are being identified and will be presented.
Stereotactic Radiosurgery for Intermediate (III) or High (IV-V) Spetzler-Martin Grade Arteriovenous Malformations: International Stereotactic Radiosurgery Society Practice Guideline
Graffeo, Christopher S. , Kotecha, Rupesh , Sahgal, Arjun , Gorgulho, Alessandra, Ma, Lijun , Régis, Jean , Sheehan, Jason P. , Yomo, Shoji , Pollock, Bruce E. , Fariselli, Laura , Levivier, Marc , Paddick, Ian , Suh, John H.

Mayo Clinic

Neurosurgery | July 11, 2024 | Volume: 96 | Issue: 2 | Pages: 298-307

10.1227/neu.0000000000003102 | PMID 38989995 Get It

BACKGROUND AND OBJECTIVES: Consensus guidelines do not exist to guide the role of stereotactic radiosurgery (SRS) in the management of patients with Spetzler-Martin Grade III-V arteriovenous malformations (AVMs). We sought to establish SRS practice guidelines for Grade III-V AVMs based on a critical systematic review of the published literature. METHODS: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant search of Medline, Embase, and Scopus, 1986 to 2023, for publications reporting post-SRS outcomes in ≥10 Grade III-V AVMs with the median follow-up ≥24 months was performed. Primary end points were AVM obliteration and post-SRS hemorrhage. Secondary end points included dosimetric variables, Spetzler-Martin parameters, and neurological outcome. RESULTS : In total, 2463 abstracts were screened, 196 manuscripts were reviewed, and 9 met the strict inclusion criteria. The overall sample of 1634 AVMs consisted of 1431 Grade III (88%), 186 Grade IV (11%), and 11 Grade V lesions (1%). Total median post-SRS follow-up was 53 months for Grade III and 43 months for Grade IV-V AVMs (ranges, 2-290; 12-262). For Grade III AVMs, the crude obliteration rate was 72%, and among Grade IV-V lesions, the crude obliteration rate was 46%. Post-SRS hemorrhage was observed in 7% of Grade III compared with 17% of Grade IV-V lesions. Major permanent deficits or death from hemorrhage or radiation-induced complications occurred in 86 Grade III (6%) and 22 Grade IV-V AVMs (12%). CONCLUSION: Most patients with Spetzler-Martin Grade III AVMs have favorable SRS treatment outcomes; however, the obliteration rate for Grade IV-V AVMs is less than 50%. The available studies are heterogenous and lack nuanced, long-term, grade-specific outcomes.
Repeat Single-Session Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations: A Systematic Review, Meta-Analysis, and International Stereotactic Radiosurgery Society Practice Guidelines
Shaaban, Ahmed , Tos, Salem M , Mantziaris, Georgios , Kotecha, Rupesh , Gorgulho, Alessandra, Ma, Lijun , Pollock, Bruce E. , Régis, Jean , Yomo, Shoji , Sahgal, Arjun , Sheehan, Jason P. , Sheehan, Jason , Mantziaris, Georgios , Fariselli, Laura , Levivier, Marc , Paddick, Ian , Suh, John H.

Mayo Clinic

Neurosurgery | June 24, 2024 | Volume: 96 | Issue: 1 | Pages: 29-40

10.1227/neu.0000000000003049 | PMID 38912814 Get It

BACKGROUND AND OBJECTIVES: Repeat stereotactic radiosurgery (SRS) for residual arteriovenous malformations (AVMs) can be considered as a salvage approach after failure of initial SRS. There are no published guidelines regarding patient selection, timing, or SRS parameters to guide clinical practice. This systematic review aimed to review outcomes and complications from the published literature to inform practice recommendations provided on behalf of the International Stereotactic Radiosurgery Society. METHODS: We performed a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive search of MEDLINE, Scopus, Web of Science, and Embase was conducted. Fourteen studies with 925 patients met the inclusion criteria. Patients were treated between 1985 and 2022. All studies were retrospective, except for one prospective cohort. RESULTS: The median patient age at repeat SRS ranged from 32 to 60 years. Four studies (630 patients) reported detailed information on Spetzler–Martin grade at the time of repeat SRS; 12.54% of patients had Spetzler–Martin grade I AVMs (79/630 patients), 46.51% had grade II (293/630), 34.92% had grade III (220/630), 5.08% had grade IV (32/630), and 0.95% had grade V (6/630). The median prescription doses varied between 15 and 25 Gy (mean, 13.06-22.8 Gy). The pooled overall obliteration rate at the last follow-up after repeat SRS was 59% (95% CI 51%-67%) with a median follow-up between 21 and 50 months. The pooled hemorrhage incidence at the last follow-up was 5% (95% CI 4%-7%), and the pooled overall radiation-induced change incidence was 12% (95% CI 7%-20%). CONCLUSION: For an incompletely obliterated AVM, repeat radiosurgery after 3 to 5 years of follow-up from the first SRS provides a reasonable benefit to the risk profile. After repeat SRS, obliteration is achieved in the majority of patients. The risk of hemorrhage or radiation-induced change appears low, and International Stereotactic Radiosurgery Society recommendations are presented.
Stereotactic Radiosurgery for Brain Metastases from Human Epidermal Receptor 2 Positive Breast Cancer: An International, Multi-center Study
Pikis, Stylianos , Ross, Richard B. , Rusthoven, Chad G. , Langlois, Anne-Marie, Lee, Cheng-chia Lee, Peker, Selçuk , Samancı, Yavuz , Toss, Salem M., Niranjan, Ajay , Wei, Zhishuo , Lunsford, Dade, Sheehan, Jason P. , Mantziaris, Georgios , Protopapa, Maria , Tos, Salem M , Kowalchuk, Roman O. , Tripathi, Manjul , Langlois, Anne-Marie, Mathieu, David , Lee, Cheng‐Chia , Yang, Huai‐Che , Zhang, Michael , Braunstein, Steve

Mayo Clinic

No container title available | June 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4481085/v1 Get It

Abstract Purpose To report patient outcomes and local tumor control rates in a cohort of patients with biopsy-proven HER-2 positive breast cancer treated with stereotactic radiosurgery (SRS) for brain metastases (BM). Methods This international, retrospective, multicenter study, included 195 female patients with 1706 SRS-treated BM. Radiologic and clinical outcomes after SRS were determined and prognostic factors identified. Results At SRS, median patient age was 55 years [interquartile range (IQR) 47.6–62.0], and 156 (80%) patients had KPS ≥ 80. The median tumor volume was 0.1 cm3 (IQR 0.1–0.5) and the median prescription dose was 16 Gy (IQR 16–18). Local tumor control (LTC) rate was 98%, 94%, 93%, 90%, and 88% at six-, 12-, 24-, 36- and 60-months post-SRS, respectively. On multivariate analysis, tumor volume (p = < 0.001) and concurrent pertuzumab (p = 0.02) improved LTC. Overall survival (OS) rates at six-, 12-, 24-, 36-, 48-, and 60-months were 90%, 69%, 46%, 27%, 22%, and 18%, respectively. Concurrent pertuzumab improved OS (p = 0.032). In this patient subgroup, GPA scores ≥ 2.5 (p = 0.038 and p = 0.003) and rare primary tumor histologies (p = 0.01) were associated with increased and decreased OS respectively. Asymptomatic adverse radiation events (ARE) occurred in 27 (14.0%) and symptomatic ARE in five (2.6%) patients. Invasive lobular carcinoma primary (p = 0.042) and concurrent pertuzumab (p < 0.001) conferred an increased risk for overall but not for symptomatic ARE. Conclusion SRS affords effective LTC for selected patients with BM from HER-2 positive breast cancer. Concurrent pertuzumab improved LTC and OS with however an increased risk for overall but not symptomatic ARE.